Genetic mutations invalidating the genes for integrin a6b4 and, in some cases, plectin are associated with junctional and simplex epidermolysis bullosa with pyloric atresia (PA-JEB and PA-EBS), respectively. These recessive inherited conditions are characterized by pregnancies with fetal bullae, pyloric atresia, polyhydramnios, and neonatal mucocutaneous blistering, which often results in early postnatal demise. To date, first-trimester DNA-based prenatal diagnosis is not applicable to affected kindred carrying as yet unidentified genetic mutations. Here, we show that first-trimester chorionic villi strongly express both integrin a6b4 and plectin, which persist throughout the pregnancy. Based on this observation, we implemented 25 prenatal diagnoses in kindred at risk for PA-EB by immunomapping, which identified three PA-JEB-affected fetuses and 22 healthy ones. In 19 cases, including the three PA-JEB pregnancies that were prematurely terminated, the results were confirmed by chorionic villous DNA-based tests, which also led to the identification of seven previously unreported mutations in the a6b4 integrin genes. Our prediction was further sustained by the birth of 22 healthy babies. These results validate chorionic villi immunofluorescence examination as a tool for prenatal diagnosis of PA-JEB and PA-EBS and indicate that this procedure could be devised for EB with muscular dystrophy, which is also associated with genetic mutations in plectin.
INTRODUCTION
Over the last decades, the exponential growth of knowledge on the molecular bases of inherited skin disorders has greatly facilitated their diagnosis, prognosis prediction, and disease management. With respect to inherited epidermolysis bullosa (EB), the characterization of the individual cutaneous basement membrane components has helped to shed light on the molecular basis of this heterogeneous group of disorders. Similar in their etiology of trauma-induced blistering and erosions of the skin and mucous membranes (Fine et al., 2000) , but widely ranging in their clinical presentation, inherited EB had traditionally been divided into three major categories: EB simplex (EBS), junctional EB (JEB), and dystrophic EB (DEB), which are characterized by tissue separation within the epidermal basal cell layer, the lamina lucida of the basement membrane, and the sublamina densa, respectively (Fine et al., 2000) . Within these three major categories, there are to date as many as 30 different recognized EB subtypes resulting from genetic mutations in 10 distinct genes encoding seven adhesion proteins, which play a critical role in the anchorage of the epidermis to the underlying dermis (Fine et al., 2000; Uitto and Richard, 2005; Has and BrucknerTuderman, 2006) . The abnormal expression and/or function of any of these proteins results in the dermal-epidermal detachment distinctive of all the EB forms. However, the nature and the combination of the genetic mutations, as well as the expression pattern of the mutated molecule in extracutaneous tissues, cooperate in determining the specific EB variant and the related phenotype (Varki et al., 2006; Varki et al., 2007) . Genetic mutations resulting in absent/ highly reduced expression of laminin 332, integrina6b4, and collagen type VII are known to cause the severe recessive EB variants Herlitz JEB (OMIM 226700), JEB associated with pyloric atresia (PA-JEB, OMIM 226730) and HallopeauSiemens DEB (OMIM 226600), respectively (Uitto and Richard, 2005) . In addition, mutations in the hemidesmomal component plectin underlie the recessive diseases EBS with pyloric atresia (PA-EBS) and EBS with muscular dystrophy (OMIM 226670) and the rare dominantly inherited form of EBS designated as EBS Ogna type (OMIM 131950) (Uitto and Richard, 2005) . In all these EB forms, immunofluorescence examination of a patient's skin biopsy shows defective expression of the involved protein, thus facilitating the identification of the causative gene and the subsequent search for mutations. As for most inherited disorders, no effective therapy is currently available for these life-threatening conditions, thus prenatal diagnosis remains the only option for pregnant women at risk for recurrence. Initially, this procedure relied upon ultrastructural analysis of mid-pregnancy fetal biopsy specimens to detect the skin abnormalities characteristic of each EB form (Rodeck et al., 1980) ; then immunofluorescence procedures were developed to gain additional information on the defective protein and mutated gene (Holbrook et al., 1993) . After identification of the EB causative genes, this approach of prenatal diagnosis was replaced by DNA-based genetic analysis of first-trimester chorionic villi, which permits an earlier assessment of the fetus phenotype (Fassihi et al., 2006) . Despite these advantages, the DNA-based prenatal diagnosis does not apply to affected kindred carrying unidentified genetic mutations. Previous studies have shown that, in the placenta, the cytotrophoblast villus stem cells strongly express the laminin receptor integrin a6b4 (Aplin, 1993; Damsky et al., 1992) . This integrin concentrates at the basal aspect of the cells and anchors them to the basement membrane rich in laminins and collagen type IV (Aplin, 1993; Damsky et al., 1992) . Based on this observation, we hypothesized that other molecules responsible for severe EB forms could be expressed in these placental structures and that immunofluorescence examination of first trimester chorionic villi could permit early prenatal diagnosis of severe EB in families at risk of recurrence even when the causative genetic mutation (s) are not yet identified. To verify this idea, we examined a series of placental villi for the expression of all the proteins known to be defective in the severe EB forms. Our analysis demonstrated that, in addition to integrin a6b4, the chorionic villi strongly express the intermediate filament binding protein plectin and validated the working hypothesis that a novel early prenatal diagnostic procedure for PA-JEB and PA-EBS can be based on chorionic villi immunostaining.
RESULTS AND DISCUSSION
Expression of the basement membrane proteins involved in the etiology of severe EB was examined in frozen samples of placental villi obtained from 10-to 15-week-gestation pregnancies at risk for diseases unrelated to EB using specific monoclonal and polyclonal antibodies. According to previously published data (Aplin, 1993; Damsky et al., 1992) , a strong immunolabeling was detected with antibodies directed against the integrin a6 and b4 subunits (Figure 1a Immunofluorescence labeling of frozen chorionic villous samples of (a-c) a healthy control and (d-i) pregnancies at risk for PA-EB using (a, d, g) monoclonal antibodies G0H3, (b, e, h) 3E1, and (c, f, i) 10F6 to integrins a6, b4, and plectin, respectively. In the chorionic villi of the healthy 11-week-gestation fetus, a comparable and intense staining signal for integrins (a) a6, (b) b4, the a6b4 heterodimer (not shown) and (c) plectin localizes at the cytotrophoblast surface and concentrates at the basement membrane zone. In the trophoblasts of the 28-and the 37-week fetuses (Table 1, samples 23, 25, respectively) , the immunofluorescence analysis showed a strong reduction of (d) integrin a6 or (h) integrin b4, respectively, thus indicating PA-JEB. The immunolabeling of (e) integrin b4 and (f) plectin of the 28-week fetus, and (g) of integrin a6 and (i) plectin of the 35-week fetus was similar with the controls. The corresponding fetuses resulted homozygous and compound heterozygous for nonsense mutations in the ITGA6 or the ITGB4 genes, respectively. Bar ¼ 68 mm.
cytotrophoblasts were also immunoreactive to anti-plectin antibodies ( Figure 1c ), whereas no immunostaining was visualized with the antibodies directed against laminin 332, and type VII collagen (not shown). Finally, a strong immunoreactivity to collagen type IV, used as positive control, was visible throughout the villous stroma at the level of basement membranes (not shown). The labeling pattern observed for both plectin and integrin a6b4 was very similar, with an immunofluorescence staining localized at the basal cell aspect of the cytotrophoblasts and at the lateral and apical areas of contact between the contiguous cells ( Figure 1a-c ). These data demonstrate that first trimester villous trophoblasts express the component of the hemidesmosomal inner plaque plectin and confirm the previously reported expression of integrin a6b4 in these placental cells (Aplin, 1993; Damsky et al., 1992) . To our knowledge, this is previously unreported. In addition, the coexpression of plectin and integrin a6b4 at the basal aspect of the cytotrophoblasts suggests the presence of type II hemidesmosomes. Indeed, several in vitro studies have shown that integrin a6b4 and plectin are the two key adhesion molecules involved in the initial steps of hemidesmosome nucleation and both are expressed in the gastrointestinal tract where rudimentary type II hemidesmosomes are detected (Green and Jones, 1996) . The severe EB forms PA-JEB and PA-EBS are genetically determined by mutations in the genes ITGA6, ITGB4, and PLEC, encoding the two subunits of the a6b4 integrin and plectin, respectively (Uitto and Richard, 2005; Has and BrucknerTuderman, 2006) . Clinically indistinguishable, these two recessively inherited conditions are characterized by pregnancies with fetal eruption of bullae, pyloric atresia, polyhydramnios, severe neonatal mucocutaneous blistering, and early postnatal demise (Uitto and Richard, 2005) . All the genetic mutations described so far in PA-JEB and PA-EBS patients cause either absence or markedly reduced expression of the mutated protein, which can be easily detected by immunofluorescence examination of a skin biopsy (Uitto and Richard, 2005) . Thus, the detection of plectin and integrin a6b4 in chorionic villi supported the rationale for investigating the feasibility of prenatal diagnosis for PA-JEB and PA-EBS by immunofluorescence examination of placental villi. Twenty-five prenatal diagnoses involving 18 kindred who had requested testing for PA-EB were evaluated by both protein immunodetection and screening of genetic mutations (Table 1 ). In 22 of the pregnancies, the test was requested because of disease recurrence risk, and therefore it was carried out on first-trimester villous samples ( (Azarian et al., 2006) . By immunofluorescence analysis, all 22 first-trimester villous cytotrophoblasts proved to be immunoreactive to the monoclonal antibodies directed against the integrin subunits a6, b4, and plectin, and with an intensity and distribution of the signal staining indistinguishable from the controls (Table 1, samples  1-22) . With respect to the genetic analyses, 10 of these pregnancies concerned previously genotyped PA-JEB kindred (Table 1 , samples 13-22), 7 of which had genetic abnormalities in the integrin b4 gene (ITGB4), whereas 3 had genetic abnormalities in integrin a6 gene (ITGA6). The other 12 cases concerned PA-EB kindred who had not been genotyped (Table 1, samples 1-12 ). In accordance with the normal expression of integrin a6b4 and plectin observed by immunofluorescence, which predicted an unaffected fetus, in all pregnancies from genotyped families, sequence analysis of fetal DNA showed the presence of at least one normal allele (Table 1 , samples 13-22), whereas in 6 out of the 12 samples of kindred who had not previously been genotyped, the implementation of mutation analysis allowed confirmation of 6 unaffected children (Table 1 , samples 1-6). For the remaining 6 villous samples, the candidate gene and the causative mutations remained unknown (Table 1 , samples 7-12). Thus, at this stage, 16 early prenatal diagnoses were based on results obtained by both immunofluorescence analysis and genetic studies. In the remaining six pregnancies at risk of recurrence, the prenatal diagnosis exclusively relied on the immunofluorescence data without further confirmation at the genetic level (Table 1 , samples 7-12). Nevertheless, after genetic counseling, the families declined further prenatal testing by fetal skin biopsy and opted for periodical follow-up to detect any possible ultrasonographic or laboratory signs of pyloric atresia that could invalidate the conclusion of the immunofluorescence tests (Lepinard et al., 2000) . As predicted, all 22 pregnancies proceeded without complications, and at birth all the newborns were healthy. During the study, prenatal diagnosis was also requested for three late gestations in which polyhydramnios and elevated amniotic fluid a-fetoprotein were associated with a positive acetylcholinesterase in kindred with no family history of PA-EB (Table 1 , samples 23-25). In one case, in utero ultrasound examination had in addition visualized extensive fetal skin blistering (Table 1 , sample 25) (Azarian et al., 2006) . In accordance with the clinical observation, immunofluorescence analysis of the chorionic villi obtained from these three fetuses showed a strong staining reduction of either the a6 (Table 1 , sample 23) (Figure 1d ) or b4 (Table 1 , samples 24, 25) ( Figure 1h ) integrin subunits, as compared with control samples of the same gestation age. Plectin immunoreactivity of the suspected PA-EB fetuses was instead comparable with the control (Figure 1c, f and i) . After genetic counseling, and in accordance with the French laws, the families opted for termination of the pregnancies. As expected, the aborted fetuses presented all clinical manifestations of severe PA-EB with extremely fragile integument and extensive areas of congenital aplasia cutis. Immunofluorescence examination of skin biopsy samples from the fetus aborted at 37 weeks showed a complete detachment of the epithelium from the underlying dermis and confirmed the defective expression of b4 integrin ( Figure S1 ). No frozen skin samples were available from the other two aborted fetuses. Subsequent mutational screening showed the presence of genetic mutations, which invalidated the expression of integrin a6b4 in the three fetuses. During this study, 14 different mutations in the ITGB4 and 2 in the ITGA6 gene were identified, 7 of which are previously unpublished. All novel mutations are predicted to impair integrin a6b4 expression. Specifically, six mutations (c591_592insC, c93delG, c2140insC, pW1240X, pR1540X within ITGB4, and pR540X in the ITGA6 gene) were nonsense or small out-of-frame insertions or deletions resulting in premature termination codon downstream of the site of the genetic lesion. One mutation (c1377-2A4G in the ITGB4 coding sequence of sample 1) was a single-base substitution, which abolishes the 3 0 acceptor splice site consensus sequence and is expected to cause an aberrant pre-mRNA processing resulting in downstream premature termination codon. In conclusion, this study demonstrates that the chorionic villi strongly express the hemidesmosomal component a6b4 integrin and its protein interactor plectin from first trimester to the end of the pregnancy. On these bases, we have developed and validated a novel prenatal test for PA-JEB that can be extended to PA-EBS. This procedure, which is relatively safe for the fetus, is simple, rapid, and accessible to all the laboratories equipped for immunohistological analysis. It also represents the only possible prenatal diagnostic approach for pregnancies either with no family history of PA-EB or at risk of recurrence but not yet genotyped. Besides establishing the phenotype of the fetus, the villi immunolabeling detects the defective polypeptide, which designates the candidate gene and facilitates the screening for genetic mutations. Indeed, given the minute amount of villi required for immunolabeling, epitope mapping can be coupled with genetic analysis in pregnancies at risk for recurrence of PA-EB carrying as yet unidentified genetic mutations. Immunodetection of integrin a6b4 and plectin represents an additional diagnostic tool for any abnormal gestation when, in addition to no family The mutated gene and the causative mutation(s) were identified after prenatal diagnosis by epitope mapping.
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Novel mutations. Samples 3 and 14, 4 and 15, 7 and 8, 10 and 11, 17 and 18, 20 and 21, 22 and 23 correspond to chorionic villous samples from consecutive pregnancies in the same family. Genetic mutations were numbered according to the translation initiation codon of the b4A (GenBank NM_001005731.1) and a6 (GenBank X53586) integrin cDNAs. The ITGB4 mutations c1141delC, c3793+2insT, and c1377-2A4G, as well as the c809delC in the ITGA6 gene, have been named as c1150delG, c3801+2insT, c1379-2A-G and c791delC, respectively, in previous publications.
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The kindred was already genotyped at the time of prenatal diagnosis; # , haplotype compatible with the paternal wild-type allele.
history of PA-EB, polyhydramnios and elevated amniotic fluid a-fetoprotein are coupled with positive acetylcholinesterase (Lepinard et al., 2000) . Our findings also indicate that prenatal diagnosis tests based on immunofluorescence detection of plectin could be devised for EBS with muscular dystrophy, which is allelic to PA-EBS (Uitto and Richard, 2005) . They also suggest that prenatal testing based on epitope mapping of fetal tissues could be applied to other inherited diseases associated with defective expression of extracutanoeus proteins present in the chorionic villi, such as the merosin-deficient congenital muscular dystrophy (OMIM 607855) and microria-congenital nephrosis syndrome (OMIM 609049), which are caused by mutations in the genes encoding the laminin chains a2 and b2, respectively (Korhonen and Virtanen, 2001 ).
MATERIALS AND METHODS
Residual chorionic villous samples from four pregnant women requesting prenatal diagnosis for unrelated diseases were used to investigate the expression of proteins defective in severe EB. The study was then extended to 25 pregnancies requesting prenatal diagnosis for PA-EB: 22 of them were at risk for recurrence of PA-EB and studied at 10-to 15-weeks gestation, whereas the remaining three were referred to us after the seventh month of pregnancy, because of abnormal ultrasound findings and elevated amniotic fluid a-fetoprotein, suggesting PA-EB (Lepinard et al., 2000) . Fourteen prenatal diagnoses involved seven mothers who had multiple pregnancies, therefore a total of 18 EB kindred were included in the cohort. The study had institutional approval and was conducted according to the Declaration of Helsinki principles. All women had received genetic counseling and gave written informed consent. An aliquot of each chorionic villous sample was processed for genomic DNA extraction and another aliquot was frozen for immunofluorescence analysis. Genomic DNA was screened for genetic mutations in the integrin a6b4 and plectin genes by PCR amplification of the exonic DNA sequences followed by denaturing high-performance liquid chromatography (DHPLC) scanning and/or direct sequencing. For immunofluorescence studies, 4-mm thick frozen sections were processed using a biotin-streptavidin-fluorescein procedure as previously described (Kanitakis et al., 1989) . Skin biopsy samples from the fetus aborted at 37 weeks were similarly processed for immunolabeling. The antibodies used were as follows: G0H3 to integrin a6 (BD PharMingen Inc., San Diego, CA); 3E1 (Chemicon International, Temecula, CA), and 450-11A (from R Falcioni, Rome, Italy) specific to the extracellular and cytoplasmic domain of integrin b4, respectively; S3-41 (from V Quaranta, Nashville, TN) to the heterodimeric a6b4; HD121 (from K Owaribe, Nagoya, Japan) and 10F6 to plectin (Santa Cruz Biotechnology Inc., Santa Cruz, CA); GB3 to trimeric laminin 332 (from JP Ortonne, Nice, France); BM165 to the laminin a3 chain; K140 to the laminin b3 chain (from P Marinkovich, Stanford, CA); U46 to the laminin g2 chain (Scaturro et al., 2003) ; CIV-22 (Dako Carpenteria, San Diego, CA) and LH7:2 (Cymbus Bioscience, Southampton, UK) to collagens type IV and type VII, respectively. The staining intensity by amplified immunofluorescence was scored as follows: þ þ , strongly positive; þ , positive; þ /À, barely detectable; À, negative.
